abstract |
A pharmaceutical composition for the treatment of type II diabetes that simulates GLP-1 and a preparation method thereof, the pharmaceutical composition contains polyethylene glycol loxenatide, a physiologically acceptable buffer with a pH value of 3.0-7.0 and a pharmaceutically acceptable buffer solution. Adjuvants are acceptable, and the pharmaceutical composition has good drug stability. |